Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.61−0.32 (-16.58%)
Close on Nov 12, 2026Market cap $313.17MP/E –Yield –
Altimmune ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Altimmune's ebitda for the twelve months ending Sep 30, 2023 was -$87.05M. For fiscal 2022 it was -$87.95M. The highest annual figure on record is -$5.96M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$87.95M | – |
| FY2021 | Dec 31, 2021 | -$96.36M | – |
| FY2020 | Dec 31, 2020 | -$54.37M | – |
| FY2019 | Dec 31, 2019 | -$21.08M | – |
| FY2012 | Dec 31, 2012 | -$5.96M | – |
| FY2011 | Dec 31, 2011 | -$11.26M | – |
| FY2010 | Dec 31, 2010 | -$22.53M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$23.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.51M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$32.92M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.23M | – |
See a number that looks wrong?